title: Prevalence of hepatitis C virus antibodies in hemodialysis patients in the area of Milan.
abstract: We studied the seroprevalence of antibodies to hepatitis C virus (HCV Ab) in a cohort of 229 chronic hemodialysis patients followed by 6 Dialysis Units in the Milan area. HCV Ab was present in 51 (22.3%) of 229 examined patients. Previous blood transfusions and surgery did not clearly influence HCV seroconversion, whereas duration of dialysis treatment seems to be strictly related to HCV Ab positivity.
authors.affiliation: Second Department of Infectious Diseases, L. Sacco Hospital, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Gubertini
authors.forename: D
authors.initials: D
authors.lastname: Scorza
authors.forename: M
authors.initials: M
authors.lastname: Beccari
authors.forename: G
authors.initials: G
authors.lastname: Buccianti
authors.forename: A
authors.initials: A
authors.lastname: Costantino
authors.forename: D
authors.initials: D
authors.lastname: Spotti
authors.forename: G
authors.initials: G
authors.lastname: Graziani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003428:Cross Infection / Q000453:epidemiology / Q000276:immunology / Q000635:transmission; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D006526:Hepatitis C / Q000453:epidemiology / Q000276:immunology / Q000635:transmission; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D006508:Hepatitis Antibodies